The PTC-CTP grant from the Alzheimer's Association funds biomarker-driven clinical trials testing combination therapies for Alzheimer’s disease and related dementias.
PTC-EM-AI Funding Program supports researchers advancing AI-discovered therapies through lead optimization and IND-enabling work to develop disease-modifying treatments for Alzheimer’s and related dementias.
Tau Pipeline Enabling Program V (T-PEP) supports researchers developing therapeutic candidates targeting tau or related mechanisms to advance potential disease-modifying treatments for tauopathies.
Prevention RFP - Alzheimer's Drug Discovery Foundation supports researchers and clinicians conducting human studies of targeted interventions, combination therapies, and drug choices to reduce dementia risk.
Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
Thome Memorial Foundation Awards Program in Alzheimer’s Disease Drug Discovery Research supports postdocs and early-career investigators studying drug discovery to improve Alzheimer’s therapies.